Related Experiment Video

Updated: Aug 9, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

510

Recent Clinical Advances on Long Non-Coding RNAs in Triple-Negative Breast Cancer

Desh Deepak Singh1, Hae-Jeung Lee2, Dharmendra Kumar Yadav3

  • 1Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur 303002, India.

Cells
|February 25, 2023
PubMed

Insights

Long non-coding RNAs (lncRNAs) show promise for treating aggressive triple-negative breast cancer (TNBC). These molecules offer new avenues for early diagnosis, treatment, and monitoring of TNBC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by heterogeneity and complex molecular pathways.
  • TNBC presents significant clinical challenges due to high metastatic potential and difficulty in management.
  • Current research explores RNA, DNA, and proteins for improved TNBC diagnosis and treatment.

Purpose of the Study:

  • To explore the role of long non-coding RNAs (lncRNAs) in triple-negative breast cancer.
  • To discuss lncRNA-based strategies for early diagnosis, treatment, and overcoming drug resistance in TNBC.
  • To highlight the potential of lncRNAs as sensitive and specific biomarkers for TNBC.

Main Methods:

  • Review of molecular advances in lncRNA regulation of TNBC.
  • Analysis of lncRNA involvement in epigenetic regulation, cell proliferation, apoptosis, invasion, and metastasis.
  • Examination of lncRNA-based diagnostic and therapeutic approaches.

Main Results:

  • LncRNAs are emerging as novel targets for TNBC treatment due to their regulatory roles.
  • LncRNAs are involved in key processes of TNBC progression, including metastasis.
  • Specific expression patterns of lncRNAs in cells and tissues make them valuable for TNBC management.

Conclusions:

  • LncRNAs offer promising avenues for the early diagnosis and targeted treatment of TNBC.
  • Understanding lncRNA mechanisms is crucial for developing effective therapies and overcoming drug resistance.
  • LncRNAs represent important biomarkers for monitoring TNBC patients and improving clinical outcomes.
Keywords:
diagnosislncRNAtargeted drug development and resistancetriple-negative breast cancer

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.0K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K